<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741542</url>
  </required_header>
  <id_info>
    <org_study_id>CTMS 20-0138</org_study_id>
    <secondary_id>HSC20210039H</secondary_id>
    <nct_id>NCT04741542</nct_id>
  </id_info>
  <brief_title>Safety of SP-420 in the Treatment of Transfusional Iron Overload</brief_title>
  <official_title>Phase 1, Open-Label, Dose Escalation Study to Assess the Safety of Sp-420 in the Treatment of Transfusional Iron Overload in Patients With MDS(Myelodysplastic Syndrome), and MF (Myelofibrosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abfero Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study enrolls patients with myelodysplastic syndrome (MDS) and myelofibrosis (MFS), with&#xD;
      transfusional iron overload and treats them with the investigational iron chelator, SP-420.&#xD;
      SP-420 may be better tolerated and safer than commercially available iron chelators. Iron&#xD;
      chelation therapy (ICT) has been shown to improve outcomes in iron overload, but adherence is&#xD;
      poor due to problems related to ease of administration, tolerability, and safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>28 Days</time_frame>
    <description>Count of adverse events induced by SP-420</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Completion at original dose</measure>
    <time_frame>28 Days</time_frame>
    <description>Number of subjects that completed the study at the original starting dose of that group</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Iron Overload</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will receive a 14mg/kg starting dose of SP-420 three times a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will receive a 28mg/kg starting dose of SP-420 three times a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will receive a 42mg/kg starting dose of SP-420 three times a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will receive a 56mg/kg starting dose of SP-420 three times a week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-420</intervention_name>
    <description>This study aims to establish the safety of SP-420 administered orally three times per week (TIW).</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <other_name>(4S)-4,5-dihydro-2-[2-hydroxy-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-4-methyl-4-thiazolecarboxylic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18&#xD;
&#xD;
          2. Diagnosis of MDS or MF with transfusional iron overload&#xD;
&#xD;
          3. Patients with MDS, will include only those with MDS Revised international prognostic&#xD;
             scoring system (IPSS-R) risk group of intermediate, high, or very high.&#xD;
&#xD;
          4. Patients with MF, will include only those with Dynamic International Prognostic&#xD;
             Scoring System-Plus (DIPSS=Plus) risk category of intermediate-1, intermediate-2, and&#xD;
             high risk.&#xD;
&#xD;
          5. Not appropriate for other iron chelation therapy, per physician&#xD;
&#xD;
          6. Received 10 or more units of packed red blood cells in the preceding 24 months and&#xD;
             remains red cell transfusion dependent&#xD;
&#xD;
          7. ECOG ≤ 3&#xD;
&#xD;
          8. ALT ≤ 3 times the upper limit of the normal range&#xD;
&#xD;
          9. Estimate glomerular filtration rate calculated using Cockroft Gault of ≥ 60&#xD;
             mL/min/1.73m2&#xD;
&#xD;
         10. Serum ferritin ≥1000 ng/ml&#xD;
&#xD;
         11. Willing to comply with all study procedures and be available for the duration of the&#xD;
             study&#xD;
&#xD;
         12. Able to take oral medication and be willing to adhere to study medication for 28 days&#xD;
&#xD;
         13. Female patient must be post-menopausal (no menses for &gt; 12 consecutive months) or&#xD;
             surgically sterile (i.e., bilateral oophorectomy, hysterectomy, or tubal&#xD;
             sterilization; must agree to completely abstain for heterosexual intercourse; or, if&#xD;
             sexually active, must agree to use 1 of the following methods for birth control from&#xD;
             the date she signs the consent form until 30 days after final dose of the study drug.&#xD;
&#xD;
               -  Progesterone implant&#xD;
&#xD;
               -  Intrauterine device&#xD;
&#xD;
               -  Combination of 2 highly effective birth control methods (e.g., diaphragm/or&#xD;
                  cervical cap with spermicide plus a condom, hormonal contraception plus a barrier&#xD;
                  method, partner with vasectomy conducted &gt;60 days before screening visit plus a&#xD;
                  hormone or barrier method&#xD;
&#xD;
         14. Male patients must agree to use 1 of the following methods for birth control from the&#xD;
             date he signs the consent form until 30 days after final dose of the study drug: be&#xD;
             surgically sterile by vasectomy conducted &gt; 60 days before screening visit plus use a&#xD;
             barrier method, or, must agree to completely abstain from heterosexual intercourse, or&#xD;
             must agree to use a combination of 2 highly effective birth control methods (e.g.,&#xD;
             diaphragm/or cervical cap with spermicide plus a condom, hormonal contraception plus a&#xD;
             barrier method), or have a post-menopausal partner plus barrier method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of kidney disease including the renal Fanconi syndrome&#xD;
&#xD;
          2. Proteinuria on urine dipstick greater than trace positive&#xD;
&#xD;
          3. Pregnant, intending to become pregnant during the study, or breastfeeding&#xD;
&#xD;
          4. Receiving another investigational drug within 30 days or 3 half-lives of the&#xD;
             discontinued investigational agent, whichever is greater, of signing consent&#xD;
&#xD;
          5. History of significant hepatic impairment, defined by Child-Pugh class C&#xD;
&#xD;
          6. Active hepatitis B or C disease, evidenced by positive viral PCR&#xD;
&#xD;
          7. Symptomatic heart failure&#xD;
&#xD;
          8. Receiving active cytotoxic chemotherapy or radiation therapy for a second malignancy&#xD;
             (hormonal therapy or topical therapy for squamous cell/basal cell cutaneous tumors are&#xD;
             allowed). Treatment of the underlying hematologic malignancy with azacytidine,&#xD;
             decitabine, venetoclax, lenalidomide, or ruxolitinib is permitted. Treatment with the&#xD;
             supportive care agents luspatercept or erythropoietin agonists is permitted.&#xD;
&#xD;
          9. Concurrent treatment with Exjade/Jadenu (deferasirox), Desferal (deferoxamine), or&#xD;
             Ferriprox (deferiprone) are not permitted. Patients are allowed to stop these&#xD;
             chelators and participate in this trial 14 days after discontinuation of the other&#xD;
             chelator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Bowhay-Carnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Epp Goodwin</last_name>
    <phone>210-450-5798</phone>
    <email>goodwine@uthscsa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mays Cancer Center, UT Health San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Manea, RN</last_name>
      <phone>210-450-1821</phone>
      <email>maneap@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Bowhay-Carnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

